UPLOAD Filing
Regen BioPharma Inc
Date: Sept. 4, 2025 · CIK: 0001589150 · Accession: 0000000000-25-009550
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 024-12654
Letter
Re: Regen BioPharma, Inc. Offering Statement on Form 1-A Filed August 29, 2025 File No. 024-12654 Dear David Koos:
September 4, 2025
David Koos Chief Executive Officer Regen BioPharma, Inc. 4700 Spring Street, Suite 304 La Mesa, CA 91942
This is to advise you that we do not intend to review your offering statement.
We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification.
We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report.
Please contact Tyler Howes at 202-551-3370 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> September 4, 2025 David Koos Chief Executive Officer Regen BioPharma, Inc. 4700 Spring Street, Suite 304 La Mesa, CA 91942 Re: Regen BioPharma, Inc. Offering Statement on Form 1-A Filed August 29, 2025 File No. 024-12654 Dear David Koos: This is to advise you that we do not intend to review your offering statement. We will consider qualifying your offering statement at your request. If a participant in your offering is required to clear its compensation arrangements with FINRA, please have FINRA advise us that it has no objections to the compensation arrangements prior to qualification. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. We also remind you that, following qualification of your Form 1-A, Rule 257 of Regulation A requires you to file periodic and current reports, including a Form 1-K which will be due within 120 calendar days after the end of the fiscal year covered by the report. Please contact Tyler Howes at 202-551-3370 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences </TEXT> </DOCUMENT>